Gemini Bio Announces the Acquisition of ORFLO Technologies
* ORFLO’s cell analysis offering to complement Gemini’s portfolio of cell culture reagents
WEST SACRAMENTO, CA, November 11, 2019 – Gemini Bioproducts, LLC (“Gemini”), a leading provider of cell culture solutions and a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), today announced the acquisition of ORFLO Technologies (“ORFLO”), an innovative life sciences instrumentation company.
Founded in 2003 by Ted Ayliffe, Ph.D., ORFLO is a supplier of cell analysis instruments including flow cytometers and cell counters, as well as their associated consumables and reagents. ORFLO’s two flagship products are the Moxi Z, a cell counter, and the Moxi Go, a benchtop flow cytometer. Through the unique combination of impedance and fluorescence-based flow cytometry, ORFLO’s Moxi Go provides an informative window into cell analysis by directly measuring fluorescence, cell count, and cell volume simultaneously.
Gemini CEO Dale Gordon stated, “ORFLO is a highly complementary acquisition for Gemini. Moxi Go and Moxi Z products will greatly enhance our offerings in the cell and gene therapy markets, providing customers real-time insights into their cells to help accelerate the pace in which they bring transformational therapies to patients. The acquisition of ORFLO demonstrates our commitment to building a world class cell processing and monitoring solution. We expect to invest additional resources into R&D and leverage our excellent customer support team for the ORFLO instruments.”
Ted Ayliffe said, “We are thrilled to join the Gemini team. After almost two decades of developing our proprietary technology, we are excited about leveraging Gemini’s dedicated commercial organization with a shared vision of further developing this technology to help reach our full commercial potential.”
Harold Blue, Managing Partner of BelHealth and Gemini Board Member, added, “The addition of ORFLO is a pivotal event for Gemini in the buildout of our cell culture solutions platform. ORFLO greatly enhances the size and dynamic of the company. ORFLO’s and Gemini’s products serve the same customer endpoints and we expect the combined portfolio to strengthen our position in the rapidly evolving cell therapy industry with a comprehensive offering.”
About Gemini Bio
Founded in 1985, Gemini is a leading provider of cell culture solutions to the scientific community across cell and gene therapy, biotechnology, and academic research. Gemini also offers contract manufacturing and regulatory consulting services. Gemini’s singular mission is to enhance human life by delivering comprehensive cell culture solutions that enable discovery, development, and production of transformational therapies. Our national sales force and international distribution network serves cell culture science worldwide. The Company is based in West Sacramento, California.
About ORFLO Technologies
Founded in 2003, ORFLO Technologies is a supplier of cell analysis instruments including flow cytometers and cell counters, consumables, and reagents. ORFLO’s two flagship products are the Moxi Go, a benchtop flow cytometer, and the Moxi Z, a cell counter. Through the unique combination of impedance and fluorescence-based flow cytometry, ORFLO’s Moxi Go provides an informative window into cell analysis by directly measuring fluorescence, cell count, and cell volume simultaneously.
About BelHealth Investment Partners
BelHealth Investment Partners, based in New York, is a healthcare private equity firm focused on lower middle market companies. BelHealth has a unique combination of investing, executive management and entrepreneurial experience. BelHealth acquires majority positions in entrepreneur-owned companies that it believes would benefit from its extensive operating and private equity investment expertise. The firm invests across three core healthcare segments: Services, Products and Distribution. BelHealth is investing from its current $350 million fund.